Wave Life Sciences (WVE) Q3 2026 earnings review
Wave clears a regulatory path, but trial costs rise fast
Wave Life Sciences, a developer of genetic medicines, cleared a key regulatory hurdle for its liver-and-lung drug while expanding its obesity trials. Revenue jumped 73% to $13 million because partner GSK selected a new liver drug candidate and owed a $12 million award. Even with that payment, rising trial and overhead costs widened the net loss to $62 million and reduced cash to $431 million.
| Revenue | $13.2M +73% from a year ago on a $12M GSK award |
|---|---|
| Net loss | $61.9M widened 15% from $53.9M a year ago |
| Cash and marketable securities | $431.0M down $60M from last quarter by our math |
| Cash runway outlook | Unchanged funded into the third quarter of 2028 |
⚖️ Verdict: 🟢 Bullish
The story got better because the Food and Drug Administration agreed to a single pivotal trial for AATD drug WVE-006, with an early approval check after one year based on blood proteins. Chief executive Paul Bolno also started the combination obesity trial with tirzepatide and confirmed that patients in the single-drug obesity study have higher starting body fat. One caution: by our math, quarterly cash use hit $60 million, leaving no cushion in the 2028 funding plan as new trials begin.
The question now is whether WVE-007 can deliver at least 5% weight loss in heavier patients after showing only a 1% drop in leaner volunteers. Either fat loss scales up in patients with more starting fat, or the drug only reshapes body composition without moving the scale enough for regulators. The Phase 2a readout will settle the debate, though management still has not set a release date.
🐂 Bull Case
FDA Agrees to One-Trial Path for WVE-006
Wave Life Sciences designs RNA medicines, which are drugs that fix or silence genetic messages inside cells. Its drug WVE-006 uses a tool called an AIMer to edit faulty RNA in alpha-1 antitrypsin deficiency (AATD), an inherited disease that damages the lungs and liver. Until now, a major risk was whether U.S. regulators would allow early approval based on blood protein levels.
In October, the company announced an agreement with the Food and Drug Administration on a two-year trial that includes a one-year check "to support potential accelerated approval based on AATD biomarkers". Chief executive Paul Bolno said this path works "without the need for a separate confirmatory trial". Regulators also cleared the company's laboratory test to measure healthy M-AAT and faulty Z-AAT proteins.
This agreement removes a major hurdle because running one trial instead of two saves years and tens of millions of dollars. Wave is also extending its RNA-editing technology to a second liver drug, WVE-008, which remains on track for a regulatory filing in the fourth quarter.
What to watch: results from the 600-milligram monthly dose of WVE-006, due in the fourth quarter of 2026. Higher levels of healthy M-AAT protein would help the drug compete against rival DNA-editing treatments.
Obesity Trials Expand to Heavier Patients and Combinations
The company's main growth project is WVE-007, an RNA-silencing drug designed to burn fat while sparing muscle by turning off a gene called INHBE. Earlier this year, a small first-stage study cut belly fat by 14% after six months, but total body weight fell only 1% because the volunteers were relatively lean. Wave wants to prove the drug works across three settings: alone, alongside standard weight-loss injections, and after patients stop taking those injections.
In the third quarter, the drugmaker began a second-stage study combining WVE-007 with weekly tirzepatide in patients with obesity and type 2 diabetes. In the ongoing single-drug trial, Bolno said starting body fat levels are "substantially higher than in the Phase 1 portion and in line with Phase 2 and 3 obesity trials". A third study testing WVE-007 as "an off-ramp for their incretin therapy" will start in the fourth quarter.
Recruiting heavier patients is essential because regulators require at least a 5% weight reduction, and Wave argues fat loss scales up when patients start with more fat. Testing the drug across liver fat, blood sugar, and cholesterol also broadens its potential market.
What to watch: results from the 600-milligram single-dose group in the first-stage study, expected in the fourth quarter of 2026. Deeper fat and weight reductions at this higher dose would strengthen the case for the larger trials.
GSK Selects Another Candidate and Triggers $12M Milestone
With no approved drugs on the market, the biotechnology group earns all of its revenue from research partnerships with larger pharmaceutical companies. Its partner GSK uses Wave's SpiNA chemistry, a specialized design for RNA-silencing drugs, to develop treatments for liver and other diseases. Ongoing research payments from the original agreement had nearly dried up by the middle of the year.
In September, GSK picked a new liver disease drug candidate built with SpiNA technology to move into development, triggering a $12 million payment. That award lifted third-quarter revenue to $13.2 million, up 73% from a year ago, while accounts receivable rose to $12.0 million because the cash will arrive in the fourth quarter. By our math, regular research revenue outside that payment was just $1.2 million.
Three more partnered projects are moving toward selection, and each chosen drug can earn up to $330 million to $375 million in future payments. Because management leaves future GSK awards out of its cash forecast, every new selection directly extends the company's funding.
What to watch: fourth-quarter cash collection and whether the initial four-year GSK research period is extended past January 2027. Selection of any of the three remaining projects would bring in additional non-dilutive cash.
🐻 Bear Case
Rising Trial Costs Leave No Room for Delay
Wave describes itself as well capitalized and repeated its forecast that cash will last into the third quarter of 2028. At the end of September, cash and marketable securities stood at $431.0 million, down from $490.6 million three months earlier.
- Quarterly cash draw: $59.6 million by our math, up from $54.0 million in the second quarter
- Research and development expenses: $53.8 million, up 17.4% from a year ago
- General and administrative overhead: $25.4 million, up 40.2% from a year ago
- Implied cash draw to reach the third quarter of 2028: about $59.5 million per quarter by our math
This math cuts against the comfortable funding message because the company is already spending at the exact ceiling required to reach its 2028 target. Over the next few months, it is launching a combination obesity study, a maintenance obesity study, a new liver trial for WVE-008, and a pivotal AATD trial. Unless overhead costs drop, adding four clinical trials will push quarterly cash use higher and shorten the runway unless GSK payments fill the gap.
What to watch: fourth-quarter operating expenses and net cash draw after the $12 million GSK payment arrives. A quarterly draw above $61 million would put the 2028 funding target at risk.
Phase 2 Obesity Readout Still Has No Date
The biggest debate around Wave is whether WVE-007 can produce enough overall weight loss in heavier patients to satisfy regulators and compete with established obesity drugs. In the first-stage study of leaner volunteers, body weight dropped only 1% after six months, well below the 5% regulatory bar.
For a third straight quarter, the press release gave no target date for the first results from the Phase 2a single-drug study in patients with a body mass index between 35 and 50. Bolno noted that dosing is ongoing across the U.S. and Europe and that starting body fat is higher, but did not say how many patients have enrolled. Until the company sets a readout date and shows actual weight loss, the belief that heavier patients will lose a larger share of weight remains an untested hypothesis.
What to watch: any timetable for the Phase 2a obesity readout at the November 4 Research Day. Continued silence on enrollment numbers or data timing would indicate the trial is recruiting slowly.
Risks this quarter didn't answer
Four standing concerns from prior quarters received no new details in the third-quarter release.
- Duchenne muscular dystrophy and Huntington's disease partnerships: neither WVE-N531 nor WVE-003 was mentioned in the release; any licensing deal or regulatory filing update on the conference call would clarify whether these programs still hold value.
- Protein levels vs DNA base editors in AATD: competitors using DNA editing have reported higher total protein levels; fourth-quarter results from the 600-milligram monthly dose of WVE-006 will test whether Wave can close the gap.
- Long-term manufacturing lease costs: operating lease liabilities sit at $43.3 million after the Lexington facility extension; the quarterly filing will show the cash commitment.
- Payments to related-party contractor SNBL: not broken out in the release; the quarterly filing's related-party footnote will show whether spending stayed elevated.
👓 Other Themes
Former Sanofi Deal-Maker Hired and Corporate Move Completed
In September, the company hired Monika Vnuk, formerly global head of partnering at Sanofi, in the newly created role of Chief Business Officer to lead licensing and alliances. That appointment aligns with the goal of finding partners for older rare-disease programs and expanding platform deals. During the quarter, the business also completed its move from Singapore to Delaware, changing its name to Wave Life Sciences, Inc. and converting ordinary shares into common stock.
💲 Other KPIs
Shrinking for a fourth straight quarter: down 5.1% from last quarter and 63.2% from a year ago by our math. Deferred revenue is upfront cash from GSK that Wave has not yet earned through research work. Because the new $12 million milestone was booked directly to revenue and receivables, the remaining backlog continues to run down at about $1.2 million a quarter.
Rising 21.8% from 167.7 million a year ago, though barely changed from 204.0 million in the second quarter. The higher share count stems from last December's stock offering and the first-quarter conversion of preferred shares. That larger share base caused net loss per share to narrow from $0.32 to $0.30 even though total net loss widened by 15.0% to $61.9 million.
🔮 Guidance
Unchanged. Management still expects its $431.0 million in cash and securities to fund operations into the third quarter of 2028, excluding the $12 million GSK payment arriving in the fourth quarter and any future awards. By our math, stretching $431.0 million across seven to7.5 quarters allows an average draw of about $59.5 million per quarter, matching this quarter's $59.6 million pace.
❓ Key Questions
When will Phase 2a obesity monotherapy data be ready?
Wave confirmed that dosing is underway in heavier patients across the U.S. and Europe, but has not given a target quarter for the first readout for three straight quarters.
What happens to the Duchenne and Huntington's programs?
Neither WVE-N531 nor WVE-003 appeared in the third-quarter release. Investors need to know whether the new Chief Business Officer is close to licensing them out or if they have been shelved.
How much will the new AATD registrational trial cost?
Quarterly cash use already hit $59.6 million, right at the ceiling allowed by the 2028 cash forecast, before the two-year WVE-006 registrational study and the maintenance obesity study begin.
Will GSK extend its four-year research term in January?
The initial four-year research window from the January 2023 deal ends in early 2027, and three partnered programs are still awaiting candidate selection.